trastuzumab deruxtecan,ruxolitinib
daiichi sankyo,novartis,astrazeneca,incyte
['gyn', 'pantumor', 'trastuzumab deruxtecan', 'gicsm', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'gucsm', '#gi', 'rux,(-crux),(-trux)']
 new #asco23 study summary for patients: #targetedtherapy trastuzumab deruxtecan effectively treats many her2-expressing cancers, in destiny-pantumor02 study #gyncsm #gicsm #gucsm #destinypantumor02
Timely, trusted, compassionate doctor-approved info from @ASCO. Signup https://t.co/2KibiNRMFU

We can't answer individual medical questions.

Retweet ≠Endorsement